Pandeia Therapeutics Limited - Accounts to registrar (filleted)

REGISTERED NUMBER: 11463856 (England and Wales)

FINANCIAL STATEMENTS FOR THE PERIOD 1 JANUARY 2022 TO 31 AUGUST 2022

FOR

PANDEIA THERAPEUTICS LIMITED

Page

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

3

DIRECTORS:

Dr J F Murray

Dr D J Grainger

F De Rubertis

SECRETARY:

The Cambridge Partnership Limited

REGISTERED OFFICE:

C/o The Cambridge Partnership Ltd

The Dorothy Hodgkin Building

Babraham Research Campus, Babraham

Cambridge

Cambridgeshire

CB22 3FH

REGISTERED NUMBER:

11463856 (England and Wales)

AUDITORS:

HBB Audit Limited

Bridge House

25 Fiddlebridge Lane

Hatfield

Hertfordshire

AL10 0SP

FIXED ASSETS

Tangible assets

4

957

1,263

CURRENT ASSETS

Debtors

5

280,123

219,023

Cash at bank

796,269

1,525,884

1,076,392

1,744,907

CREDITORS

Amounts falling due within one year

6

247,747

116,338

NET CURRENT ASSETS

828,645

1,628,569

TOTAL ASSETS LESS CURRENT
LIABILITIES

829,602

1,629,832

CAPITAL AND RESERVES

Called up share capital

5,062

Share premium

4,090,905

Retained earnings

(3,266,365

)

(2,466,135

)

SHAREHOLDERS' FUNDS

829,602

1,629,832

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 5 October 2022 and were signed on its behalf by:

Dr J F Murray - Director

1.	STATUTORY INFORMATION

Pandeia Therapeutics Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Computer equipment

-

20% on cost

Taxation

Taxation for the period comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Research and development

Expenditure on research and development is written off in the year in which it is incurred.

Foreign currencies

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Hire purchase and leasing commitments

Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the period was 3 (2021 - 3 ) .

4.	TANGIBLE FIXED ASSETS

Computer

equipment

£

COST

At 1 January 2022

and 31 August 2022

2,298

DEPRECIATION

At 1 January 2022

1,035

Charge for period

306

At 31 August 2022

1,341

NET BOOK VALUE

At 31 August 2022

957

At 31 December 2021

1,263

5.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

31.8.22

31.12.21

£

Trade debtors

1,525

Other debtors

278,598

217,498

280,123

219,023

6.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

31.8.22

31.12.21

£

Trade creditors

241,446

112,629

Other creditors

6,301

3,709

247,747

116,338

7.	DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the Auditors was unqualified.

Paul Arthur Rees Skipper (Senior Statutory Auditor)

for and on behalf of HBB Audit Limited

Pandeia Therapeutics Limited - Accounts to registrar (filleted) - small 18.2

Pandeia Therapeutics Limited - Accounts to registrar (filleted) - small 18.2